TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00662467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin + clopidogrel
Description: Dual therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin + clopidogrel + warfarin
Description: Triple therapy
Study: NCT03209128

Intervention type: RADIATION
Intervention: Irradiation prophyllactique cérébrale
Description: Irradiation prophyllactique cérébrale
Study: NCT00835211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Acetate 0.2 mg Tablets
Description: 4 x 0.2 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDAVP® 0.2 mg Tablets
Description: 4 x 0.2 mg, single-dose fasting
Study: NCT00749112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab, Rituximab
Description: Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
Study: NCT04529486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Before applying the tape, it was checked whether the children were allergic. Tape was first started from the distal part of the fingers and taped with 0% tension with Kinesio Taping Functional Correction Technique. Another I tape was applied from palmar area of the hand to spina scapula for supination of the forearm and external rotation of the shoulder with %0 tension to make functional correction (Figure 2). Kinesio Taping Functional Correction method is suggested to be done with 75% of tension but for children, we applied it with 0% tension to minimize the shear effects to the skin4. Kinesio Tex Light Touch Plus tape was used for taping application (Kinesio Co., USA).
Study: NCT03614052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride 0.4 milligrams
Description: Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
Study: NCT03347370

Intervention type: DRUG
Intervention: SC Peginterferon beta-1a
Description: All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).

Intervention type: DRUG
Intervention: SC interferon beta-1a
Description: All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).

Intervention type: DRUG
Intervention: SC interferon beta-1b
Description: All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product.
Study: NCT03180619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet administered orally once daily
Study: NCT03635450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of hCT-MSC
Description: Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of hCT-MSC
Description: Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.
Study: NCT01736761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir, Ritonavir and Rilpivirine
Study: NCT04381039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole
Description: 3D printing insole (Nylon), 3D printing insole (TPU), CNC machine insole (EVA), shoe only
Study: NCT00892840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once daily, 14 days
Study: NCT01809093

Intervention type: BIOLOGICAL
Intervention: Blood draw
Description: 3-4 tablespoons of blood will be drawn, one time.
Study: NCT00470834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride
Description: 0.5mg dutasteride (Investigation Product)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: making placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: 50 mg Casodex or generic equivalent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bicalutamide
Description: 50 mg Casodex or generic equivalent
Study: NCT03662581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Group Program
Description: The mindfulness program has the following aims (Iacono, 2018): to teach mindfulness skills for stress reduction, self-compassion, and dealing with difficult thoughts and emotions, to promote an integrative concept of health, which treats the whole person, to promote community building and positive relationships, and to capitalize on the power of groups to:~1. Foster peer-to-peer learning and support when it comes to coping with life challenges~2. Combat isolation~3. Increase efficiency, quality, and timeliness of care
Study: NCT03608358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: 10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg placebo to match
Description: 10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10 mg placebo to match
Description: 10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg placebo to match
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 5 mg placebo to match
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saxagliptin 5 mg
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
Study: NCT03284892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOC program
Description: A once-daily, 7-day SOC program, including oral-motor exercise, sensory stimulation and lubrication, and safe-swallowing education.
Study: NCT00305461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Effect of Ciclesonide on Quality of Life

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Effect of Ciclesonide on Quality of Life
Study: NCT02765009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diuretics
Description: Used to reduce fluid overload as evidenced by weight gain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin
Description: Used to reduce fluid overload in addition with diuretics in hypoalbuminemic patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid restriction
Description: Used to reduce fluid overload

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: renal replacement
Description: Used to reduce fluid overload in patients with renal replacement
Study: NCT00443963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Magnesium
Description: PPI compared to H2RA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Magnesium
Description: PPI compared to H2RA
Study: NCT04585061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: 1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: 1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality device (Harga Miniso Vr Glass 3d terbaru)
Description: Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol
Description: Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized while xylitol tablet putted under tongue
Study: NCT04600271

Intervention type: DRUG
Intervention: Crystalloid Solutions
Description: exposure

Intervention type: DRUG
Intervention: Colloid Blood Volume Expanders
Description: exposure

Intervention type: OTHER
Intervention: blood replacement
Description: exposure

Intervention type: DRUG
Intervention: Diuretic
Description: exposure

Intervention type: DRUG
Intervention: noradrenaline
Description: exposure

Intervention type: DRUG
Intervention: Non-Steroidal Anti-Inflammatory Analgesics
Description: exposure
Study: NCT03761862

Intervention type: PROCEDURE
Intervention: Neural Therapy
Description: Neural therapy is a form of alternative medicine in which local anesthetic is injected into certain locations of the body in an attempt to treat chronic pain and illness.

Intervention type: PROCEDURE
Intervention: Neural Therapy
Description: Neural therapy is a form of alternative medicine in which local anesthetic is injected into certain locations of the body in an attempt to treat chronic pain and illness.
Study: NCT02360683

Intervention type: OTHER
Intervention: patients with Parkinson's disease
Study: NCT03515317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LoRETA Z-score NF
Description: LoRETA Z-score NF will be conducted using a 19-lead cap (Electrocap, Inc), which will be placed on the head according to the standard approach of the international 10-20 system with linked ear and ground reference. After the caps will be less than 5 kΩ. During each session, the participants will sit in front of a computer screen on which predesigned games or animations related to the LoRETA Z-score training are played and instructions regarding the inhibitory and reward aspects of the training are taught.
Study: NCT05829122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty
Description: In this study, patients with various causes of pupillary dilatation were recruited, and medical records and ophthalmology examinations, including slit-lamp examination, visual acuity, corrected visual acuity, intraocular pressure, pupil diameter, pupil area, corneal endothelial cell count fundus examination, and photophobia score, were collected. Those who met the recruitment criteria underwent modified iris cerclage. The modified iris cerclage was performed by making four clear corneal incisions, suturing the iris 3-4 times consecutively between each two incisions, completing 360 degrees of iris suturing in sequence, and finally tying the knot intraocularly to complete the iris cerclage.
Study: NCT05774860

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01504698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advice and exercise-based treatment plus joint manipulation
Description: The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment plus joint manipulation.The areas and frequency of manipulative treatment will be determined by the chiropractor and will consist of high-velocity, low-amplitude manipulation and/or mobilization to the spine and/or the extremities.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advice and exercise-based treatment
Description: The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment. However, assisted stretching is not allowed as this will approach mobilization.
Study: NCT02351024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXP005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn®
Study: NCT01163760

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A
Description: daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A
Description: daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A
Description: daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: ocufilcon D
Description: daily disposable contact lens
Study: NCT03515317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theta/beta NF
Description: The goal of theta/beta NF is to increase the beta power(13-20 Hz) and simultaneously inhibit the theta power (4-8 Hz) relative to a baseline assessed at the beginning of a training session. The electrodes will be placed on Fz and Cz with a linked ear model(A1). The study will use both visual and auditory feedback. Each participant will sit in front of a computer screen on which predesigned games or animations related to the training criteria are played and instructions regarding the inhibitory and reward aspects of the training are taught. The threshold will be set according to 5-min baseline EEG measurements before each session. The thresholds are the mean amplitude of the beta and the theta in 5-min baseline EEG.
Study: NCT01425580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: 1.8 mg s.c. (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg s.c. (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: 4 mg p.o. (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: 4 mg p.o. (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg p.o. (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg p.o. (BID)
Study: NCT01481194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV on day 1 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 15 mg orally on days 1-14 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 IV on day 1 of a 21-day cycle
Study: NCT05547009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended-learning group
Description: The BL program included paced, asynchronous online learning modules and scheduled online activities with strategic face-to-face lectures. Resources: 1) Moodle platform: it was used as a virtual communication platform. 2) Online syllabus: an online specific syllabus about cardiac physiotherapy was developed. 3) Online glossary: an online glossary performed by the teacher was available for the students. 4) Online videos: several videos of international and national scientific societies were provided. 5) Websites: several links to websites of international and national scientific societies such as the European Society of Cardiology, the American Heart Association or the World Heart Federation were used. 6) Online activities: five four-question online activities were created. 7) Apps, using the app Ariadna to prevent from cardiovascular risk and look for defibrillators around; 8) Online tutorship, through an online communication platform (Blackboard Collaborate).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face learning group
Description: The FLG included: 1) Face-to-face classes; 2) Hardcopy syllabus; 3) Hardcopy scien-tific societies information; 4) Face-to-face activities: four questions per each theme; 5) Hardcopy glossary; and 6) Face-to-face tutorships. In all cases, the content of the infor-mation provided was the same as the information provided to the BLG, although in a face-to-face design.
Study: NCT04114617

Intervention type: OTHER
Intervention: Starch-thickened liquids
Description: Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.

Intervention type: OTHER
Intervention: Xanthan-gum thickened liquids
Description: Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.

Intervention type: COMBINATION_PRODUCT
Intervention: Barium concentration
Description: Commercially available barium products diluted to different concentrations (i.e., 20% w/v, 40% w/v) through the addition of water
Study: NCT01127828

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arla Yoghurt with no probiotic
Description: two servings of 200 ml of investigational products per day
Study: NCT01163760

Intervention type: DEVICE
Group type: OTHER
Intervention: ocufilcon D
Description: daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: ocufilcon D
Description: daily disposable contact lens
Study: NCT04258982

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05210738

Intervention type: DEVICE
Intervention: Single incision sling
Description: Single incision sling is used to treat occult SUI

Intervention type: DRUG
Intervention: Bulkamid bulking agent
Description: Urethral bulking by Bulkamid is used to treat occult SUI
Study: NCT01223365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER
Description: Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
Study: NCT02629094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inspra /Eplerenone
Description: Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
Study: NCT02024932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVS857
Description: BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVS857
Description: BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVS857
Description: BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVS857
Description: BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
Study: NCT03020641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum
Description: Low pressure pneumoperitoneum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pneumoperitoneum pressure
Description: standard pneumoperitoneum pressure